Canada Markets close in 1 hr 24 mins
  • S&P/TSX

    17,975.12
    +30.24 (+0.17%)
     
  • S&P 500

    3,800.27
    +32.02 (+0.85%)
     
  • DOW

    30,959.83
    +145.57 (+0.47%)
     
  • CAD/USD

    0.7852
    +0.0006 (+0.0785%)
     
  • CRUDE OIL

    52.97
    +0.61 (+1.17%)
     
  • BTC-CAD

    46,349.83
    -111.38 (-0.24%)
     
  • CMC Crypto 200

    717.93
    +2.73 (+0.38%)
     
  • GOLD FUTURES

    1,839.50
    +9.60 (+0.52%)
     
  • RUSSELL 2000

    2,150.96
    +27.76 (+1.31%)
     
  • 10-Yr Bond

    1.0920
    -0.0050 (-0.46%)
     
  • NASDAQ

    13,185.72
    +187.22 (+1.44%)
     
  • VOLATILITY

    22.64
    -1.70 (-6.98%)
     
  • FTSE

    6,712.95
    -7.70 (-0.11%)
     
  • NIKKEI 225

    28,633.46
    +391.25 (+1.39%)
     
  • CAD/EUR

    0.6475
    -0.0015 (-0.23%)
     

Zhang Investor Law Alerts Investors to Deadline in Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc. – RETA

Zhang Investor Law P.C.
·2 min read

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 and August 7, 2020, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=reata-pharmaceuticals-inc&id=2468 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

如果您想加入这个集体诉讼案,请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=reata-pharmaceuticals-inc&id=2468

If you wish to serve as lead plaintiff, you must move the Court before December 14, 2020 DEADLINE. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose, among other things: the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of Friedreich’s ataxia (“FA”) in the U.S. without additional evidence; as a result, it was foreseeably likely that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
info@zhanginvestorlaw.com
tel: (800) 991-3756